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Abstract
The microbiota has a strong influence on health and disease in humans. A causative shift
favoring pathobionts is strongly linked to diseases. Therefore, anti-microbial agents selec-
tively targeting potential pathogens as well as their biofilms are urgently demanded. Here
we demonstrate the impact of ethyl pyruvate, so far known as ROS scavenger and anti-
inflammatory agent, on planktonic microbes and biofilms. Ethyl pyruvate combats prefera-
bly the growth of pathobionts belonging to bacteria and fungi independent of the genera
and prevailing drug resistance. Surprisingly, this anti-microbial agent preserves symbionts
like Lactobacillus species. Moreover, ethyl pyruvate prevents the formation of biofilms and
promotes matured biofilms dissolution. This potentially new anti-microbial and anti-biofilm
agent could have a tremendous positive impact on human, veterinary medicine and techni-
cal industry as well.
Introduction
Undoubtedly, antibiotics have significantly improved human health and life expectancy. None-
theless, we have to keep in mind that antibiotics may lead to a perturbation of the existing
physiological/beneficialmicrobiota balance which often results in the emergence of potentially
pathogenic microbes, so called pathobionts. It is now well accepted that a disturbed gut micro-
biota is a main reason for an increased susceptibility to subsequent chronic diseases such as
adiposity, metabolic syndrome, inflammatory diseases, cancer and neurological disorders [1–
3]. Moreover, a disturbed vaginal microbiota during pregnancy seems, e.g. through the use of
antibiotics or hormonal changes, to be responsible or at least to attribute for preterm birth and
to influence the development of the neonate immune system and the susceptibility for chronic
diseases including obesity [4].
The ability of microbes to form a biofilm on biological as well as on non-biological surfaces,
a highly structured community of microbes encased in a self-produced protective extracellular
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matrix, presents another great challenge in medicine and industry [5]. In this regard, biofilm-
associated infections are notoriously resistance to both conventional antimicrobial agents and
host immune system [6]. Biofilm-associatedmicroorganisms show a 100 to 1,000-fold increase
in anti-microbial tolerance compared with planktonic cells [7] and have important negative
effects on human health. Examples are Pseudomonas aeruginosa infections in cystic fibrosis,
Staphylococcus epidermidis- and Staphylococcus aureus-related implant infections, recurrent
urinary tract infections, and periodontal diseases [8]. In summary, antibiotic tolerance mecha-
nisms in biofilms include failure of antibiotics to penetrate biofilms, a slow growth rate, an
altered metabolism, the appearance of persister cells, an extracellular biofilmmatrix and Quo-
rum-sensing.
The emergence and spread of microorganisms resistant to multiple anti-microbial agents is
another great challenge to the medicine and a serious threat to global public health affecting all
parts of the world. However, while resistance rates continue to rise, the rate of antibiotic dis-
covery has dropped substantially. Sadly, only a few new agents have recently been approved
and are available [9]. Therefore, there is an urgent need for new approaches in the field of anti-
microbial therapy, having the capacity to eradicate biofilms as well.
Ethyl pyruvate (EP), a simple ester of pyruvate, seems to meet such a demand. First nota-
tions of biological effects of EP came from studies showing its capability to ameliorate intestinal
or hepatic injury during experimental ischemia, reperfusion and endotoxemia by acting as a
ROS scavenger and suppressor of pro-inflammatory cytokines.Many putative targets of EP
have been supposed to explain its beneficial effects in mammalian cells [10]. Recently, we have
shown that EP effectively inhibits the growth of cells relying predominantly on glycolysis [11].
Its auspicious anti-tumor [12] and anti-trypanosome activity [13] corroborate the assumption
that EP directly interferes with glucosemetabolism. Target analysis revealed that EP inhibits
enzymes of the glycolytic and para-glycolytic pathway, such as the glyoxalase 1 (GLO 1), and
pyruvate kinase (PK) [13, 14]. Accordingly, EP causes depletion of cellular ATP and affects
mitochondrial oxidation via induced accumulation of the toxic methylglyoxal, respectively
[11].
Against this background we deduced that many of those cells and microbes relying mainly
on glucose oxidation should be sensible to EP treatment. Therefore, we launched a comprehen-
sive study to investigate the effect of EP on (i) a large number of different aerobic and anaerobic
pathobionts with clinical significance including yeast cells and fungi; (ii) on pathobionts with
specific resistance mechanisms and (iii) on mature and developing biofilms.
Here, we display new properties of EP as pathobiont-selective anti-microbial activity with
an additional high potential as a novel anti-biofilm agent. In this regard we present evidence
that EP has anti-microbial properties against both planktonic cells and biofilms of pathobionts
and against microorganisms with clinical relevant resistance. Advantageously, EP shows
reduced anti-microbial activities against symbiotic microorganisms such as Lactobacillus spe-
cies. Surprisingly, ethyl lactate (EL) that differs from EP by two protons only is lacking anti-
microbial activities at all (Fig 1).
Materials and Methods
Microorganisms and growth condition
Clinical isolates of Candida spp. were maintained on Sabouraud dextrose agar (Oxoid, Wesel,
Germany) and incubated at 37 °C for 24 h. Lactobacillus spp. were maintained on de Man
Rogosa Sharpe (MRS) agar (Oxoid) and blood agar (Carl Roth GmbH, Karlsruhe, Germany),
followed by incubation at 37 °C, 5% CO2 for 24–48 h. Gram-negative bacteria, particularly
Escherichia coli were maintained on blood agar and incubated at 37 °C for 24 h. Subsequently,
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species level identification was done using the Matrix-assisted laser desorption ionization time-
of-flight (MALDI-TOF)mass spectrometry (bioMérieux,Marcy I’Etoile, France). All identified
microbes were stored at -80°C in a preservative Cryobank tubes (CRYOBANKTMMast Group
Ltd., Merseyside, UK) according to the manufacturer’s instruction.All strains were isolated
from clinical specimens.
MALDI-TOF-MS based microbe identification
The automated MALDI-TOF was performed following standard protocol (bioMérieux,Marcy
I’Etoile, France). Freshly growing pure microbial cells and control cells (Escherichia coli) were
directly analyzed (VITEK1-MS, bioMérieux,Marcy I’Etoile, France). The sample spectra
were compared to an extensive database of spectra from bacterial species by VITEK1-MS
proofing, which allow us to accurately identify the microorganism in question.
Determination of the Minimum Inhibitory Concentration of Candida
species
Minimum Inhibitory Concentrations (MIC) of EP were determined for planktonic Candida
spp. using sterile flat-bottom 96-well microtiter plates (Cellstar1Greiner Bio-One, Fricken-
hausen, Germay) according to EUCAST guideline [15]. The RPMI-1640 medium (Sigma-
Aldrich, Life science) supplemented with glutamine, and glucose to a final concentration of 20
g/L, pH 7.0, was sterilized using a 0.22-μm filter (TPP1, Techno Plastic Products, Trasadingen,
Switzerland). Serial two-fold dilutions of the EP were prepared in this medium in the 96-well
plate to obtain a final concentration range of 0.39 to 200 mM. Subsequently, 100 μL standard-
ized working yeast suspension was inoculated into each column containing the EP and growth
control column, which provided the required final inoculumdensity of 0.5–2.5 x 105 CFU/mL.
Afterward, the plates were incubated at 37°C for 24 h. Growth inhibition was determined visu-
ally and confirmed by spectrophotometry at 600 nm by a microdilution plate reader (Anthos
htIII Microsystem, Krefeld, Germany). The lowest concentration at which there was no turbid-
ity or growth compared to growth in the EP-free well (growth control) was regarded as
Fig 1. Graphical abstract of anti-microbial activity of ethyl pyruvate. Fingerprints of non-disinfected hands on blood agar containing ethyl pyruvate
(middle) ethyl lactate (right) and medium (left). The microbes displayed at the circumferences of the agar plates depict a selection of microbes investigated in
the present study. Plates were incubated at 37˚C for 48 h.
doi:10.1371/journal.pone.0162919.g001
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Minimum Inhibitory Concentration (MIC) of the compound. Quality control was done by tak-
ing column 11 as a growth control and column 12 as a sterility control (n = 3).
Determination of the Minimum Inhibitory Concentration of bacteria
The MICs of EP against bacteria isolates were determined on a sterile, round-bottom 96-well
microtiter plate (Greiner Bio-One, Frickenhausen, Germany) as describedby [16, 17] with
minor modifications. Serial two-fold dilutions of the EP were prepared in standardized LAB
susceptibility testing medium (LSM) broth formulation, essentially consisting of a mixture of
Iso-Sensitest (ISO) broth (90%) and (MRS) broth (10%) (Oxoid) adjusted to pH 6.7 for Lacto-
bacillus spp. and Müller Hinton broth for Escherichia coli to obtain the final concentration
ranging from 0.39 to 200 mM. Subsequently, 50 μL standardized working bacterial suspension
was inoculated into each column containing the EP and growth control, which provided the
required final inoculumdensity of 5 x 105CFU/mL. A volume of 100 μL of mediumwas trans-
ferred into column 12 as sterility control. Afterward, the plates were incubated at 37°C for 24 h
for Escherichia coli or at 37°C, 5% CO2, for 24–48 h for Lactobacillus spp. Growth inhibition
was determined visually and confirmed by spectrophotometry at 600 nm by a microdilution
plate reader (n = 3).
Determination of Minimum Bactericidal Concentration and Minimum
Fungicidal Concentration
Minimum Bactericidal Concentration (MBC) and Minimum Fungicidal Concentration (MFC)
were determined by sub-culturing samples (10 μL) having a value of higher or equal to the
MIC value onto Sabouraud dextrose agar for Candida spp., blood agar, and MRS agar for
Escherichia coli and Lactobacillus spp., respectively. The highest dilution that yielded no single
microbial colony was considered as MBC for bacteria isolates and MFC for yeast isolates
(n = 3).
Agar macrodilution test
To evaluate anti-microbial activity of EP in agar against a wide panel of isolates namely Derma-
tophytes (obtained from INSTAND e.V., Society for Promoting Quality Assurance in Medical
Laboratories, Duesseldorf, Germany), Candida spp., and Aspergillus spp. and other moulds, Sal-
monella spp., Campylobacter spp., Gram-positive cocci, Escherichia coli, Lactobacillus spp.,Heli-
cobacter pylori, Clostridium spp., Gram-negative oxidative positive and non-spore forming
bacteria (all obtained from clinical specimens),media containing EP with different concentra-
tions was prepared. Briefly, for fungal isolates, Sabouraud dextrose agar plates (Sifin, 2% glu-
cose chloramphenicol agar) with different concentrations of EP (0, 1, 5, 10, 20 and 40 mM)
were prepared. Afterward, all dermatophytes were first grown on Sabouraud dextrose agar. To
ensure a homogeneousmicrobial suspension for inoculation, the isolates were rubbedwith 5%
Tween 80 in Sabouraud broth. Thereafter, aliquots of 5 μL of this suspension were inoculated
on Sabouraud dextrose agar plates containing the corresponding concentrations of the EP.
Subsequently, the plates were incubated at 30°C for 21 days. Standardized bacterial cells sus-
pension were cultured onto Nutrient broth (NB), Tetrathionate broth (TB), blood agar, Bru-
cella broth medium, de Man Rogasa and Sharpe (MRS), Brain Heart Infusion (BHI) with or
without EP under aerobic, microaerophilic or anaerobic conditions depending on the microbi-
ological characteristics of tested isolates for 24–120 h. Finally, plates were examined for the
growth of tested pathobionts.
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Biofilm formation
To evaluate the effect of ethyl pyruvate (EP) and ethyl lactate (EL) on Candida albicans bio-
films during the developmental phase, biofilm formation was done in a 96-wells plate. Briefly,
overnight grown colonies of Candida albicans were transferred into suspensionmedium (bio-
Mérieux, Marcy I’Etoile, France) and 800 μL of the suspension was transferred into a cuvette
and adjusted to an O.D. value of 2 (~ 108 CFU/mL) at 600 nm using a spectrophotometer
(Pharmacia Biotech Ultrospec 2000, Cambridge, UK). Subsequently, the yeast cell suspension
was adjusted to 1 x 106 CFU/mL in RPMI-1640 medium and seeded onto 96-well plates. After-
ward, plates were incubated at 37 °C for 90 min to induce adhesion [18]. After this adhesion
phase, mediumwas aspirated, non-adherent cells were removed and plates were washed by
sterile 10 mM PBS (Gibco, Life Technologies, Germany). Following washing, 100 μL of differ-
ent sub-inhibitory concentrations of EP (0, 0.2, 0.4, 0.5, 0.56, 0.6 and 0.8 x MIC) were prepared
in RPMI-1640 medium and transferred into each well containing the pre-washed biofilms.
Thereafter, the plates were further incubated at 37 °C for 24–48 h until formation of mature
biofilms occurred. To evaluate the effect of EP on pre-formed biofilms, yeast cells were sus-
pended in RPMI-1640 medium, transferred into 96-wells plate and incubated at 37 °C for 24h.
Afterward, EP at different concentrations (0.5, 1, 2, 4, and 8xMIC) was added into plates con-
taining matured biofilms and incubated for further 24 h. At each step of the experiment, the
adhered biofilms were confirmed by observation using an inverted microscope (Motic AE31,
Ted Pella, Inc. CA, USA). Finally, biofilm formation inhibition and destructionwere quantified
by XTT assay as describedbelow. Similar procedure was implemented for ethyl lactate (EL)
and Amphotericin B (AmpB) (n = 3).
XTT reduction assay
Biofilm formation inhibition and destructionwere quantified by the colorimetricXTT reduc-
tion assay (Roche Applied Science,Mannheim, Germany) according to the manufacturer’s
instruction. Briefly, a mixture of 5 mL of XTT labeling reagent (1mg/mL) and 0.1 mL electron-
coupling reagent (1.25 mM; PMS, N-methyldibenzopyrazine methyl sulfate) was prepared.
Next, 100 μL of RPMI-1640 mediumwas transferred into 96-well culture plates followed by
addition of 50 μL XTT labeling mixture solution. This was followed by incubation of the plates
at 37 °C for 4 h. Finally, the color change of the solution was measured spectrophotometrically
at 492 nm with a multimodemicroplate reader (TECAN, Grödig, Austria).
Microscopic assay
To evaluate the effect of EP on biofilm formation, Candida albicans biofilms were formed on
ThermanoxTM plastic cover slips (NUNC, Rochester, NY, USA) in a 12-wells plate (Cellstar1
Greiner Bio-One, Frickenhausen, Germany) by dispersing 3 mL of 1x 106 cells/mL suspension
in RPMI-1640 medium and incubating at 37°C for 90 min to allow cell adherence. Afterward,
the plastic cover slips containing the biofilms were transferred to sterile 12-well plate contain-
ing 3 mL of RPMI-1640 mediumwith or without EP. The plates were then incubated at 37°C
for further 24 h. Thereafter, cover slips with biofilms were transferred to glass microscopic
slides, stained with Calcofluor white solution (Polysciences, Inc, Warrington, USA) and incu-
bated at 25°C for 1 min. Finally, the stained biofilms were examined by a fluorescencemicro-
scope with ultraviolet light (excitation 340 to 380 nm with 430 nm suppression) at a
magnification of x10 (Leica, Germany). In order to evaluate the effect of EP on the destruction
of matured Candida albicans biofilms, yeast cells suspended in RPMI-1640 mediumwere
transferred into 96-well plate and incubated at 37°C for 24 h. Afterward, the mediumwas
aspired and a new RPMI-1640 mediumwith or without EP (0.5, 1, 2, 4 and 8xMIC) was added
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and incubated at 37°C for further 24 h. Finally, the effect of EP on matured biofilms was exam-
ined under an inverted microscope.
Biofilms formation in silicone tubes and analysis by scanning electron
microscope
Biofilms were allowed to generate in a silicone tube system under a dynamic condition. Tap
water from a public water distributor was used as the source of biofilm-formingmicroorgan-
isms. Briefly, at a flow rate of 200 mL/h tape water was pumped through a silicone tube with an
inner diameter of 2 mm of (Carl Roth, Karlsruhe, Germany) at 30°C for 14 days. Afterward, 3
cm-pieces of the silicone tube were cut before treatment (control) and the remaining tube was
immersed in 50 mM phosphate-buffered EP, EL and Pen/Strep (100 units/μg/mL correspond-
ing to 0.28 and 0.17 mM for Pen and Strep, respectively) solutions for further 24 h. Next, the
cut piece were emptied and sealed at both ends. Subsequently, the outer surface was treated
with 70% ethanol and rinsed with sterile distilledwater. Afterward, the tubes were cut longitu-
dinally over the entire surface into two pieces and then dipped into LB broth followed by
detachment of the biofilm through a vigorous vortex for 2–3 min. Subsequently, 0.1 mL of a
1:10 diluted suspension was seeded onto LB agar plates and incubated at 37°C for 5 days. To
determine the time-dependency the silicone tubes were analysed at different time points e.g. at
0, 4, 8 and 24 h.
Scanning electron microscopy
To examine the ultrastructuralmorphology of the biofilm, scanning electronmicroscopy was
performed. First, 10 mm long pieces were cut from silicone tubes containing biofilms treated
with 50 mM EP. Second, to prevent drying each piece was instantly submerged in 0.1 M PBS
and cut longitudinally, resulting in two halfpipe-shaped specimens. Specimens were washed in
0.1 M PBS, pH 7.2, fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, at25°C for 1 h.
Then, the specimens were washed three times in the same buffer and post-fixedwith 1%
osmium tetroxide in 0.1 M cacodylate buffer for 2 h and dehydrated in an increasing series of
ethanol (30%, 50%, 70%, 90% and absolute ethanol) for 30 min each. After critical-point-dry-
ing (CPD 030, Bal-Tec, Liechtenstein) specimens were mounted on SEM sample carrier and
coated with gold-palladium (90/10) using a sputter coater (MED 020, Bal-Tec, Liechtenstein).
The biofilm was inspected at different magnifications with a scanning electronmicroscope
(LEO 1430, Zeiss, Oberkochen,Germany).
Data analysis
At first MIC data was entered to excel spreadsheet version 2013 and descriptive statistic was
employed to demonstrate the distribution of isolates. Student’s t-test and one-way ANOVA
were used to analyze the tested microbes using GraphPad Prism version 5 (San Diego, USA).
The data were expressed as mean ± SEM. P-value<0.05 was considered as statistically
significant.
Results
Pathobiont-selective activity of ethyl pyruvate against microbes of vaginal specimensCan-
dida spp. are key pathobionts in vulvovaginal candidiasis that results mainly from the loss of
normal Lactobacillus-predominant vaginal microbiota that is mostly due to uncontrolled and
frequent antibiotic intake [19]. We have chosen representative microorganisms of the vaginal
microbiota for studying the effect of EP on individual species. The number and type of
Ethyl Pyruvate Combats Biofilms
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microbial isolates identified from vaginal specimenwere subsequently used to determine the
growth inhibitory activity of EP. Altogether, 147 isolates were obtained from vaginal speci-
mens. Among these, Candida isolates were the predominant, which accounted for 73.5% of the
total isolated microbes followed by Lactobacillus spp. (21%) and E. coli (5.4%) (Table 1). The
minimum inhibitory concentration of EP (MICEP) against the depicted isolates of Candida
albicans (n = 57), Candida tropicalis (n = 10) and Candida parapsilosis (n = 15) were similar
(25±0 mM), irrespective of the genetic make-up of the strains of each species. A slightly higher
concentration of EP was required to inhibit the growth of Candida glabrata (n = 11) (28.41
±4.87mM). Among the tested yeasts isolates, Candida krusei (n = 5) was the most susceptible
one with a MICEP value of 12.5±0 mM. Furthermore, the MICEP values of all yeast isolates
except Candida glabrata were similar to the minimum fungicidal concentration (MFCEP)
value. Higher MICEP values were ascertained for Escherichia coli isolates (50±0 mM). In con-
trast, the MICEP values for Lactobacillus spp., particularLactobacillus jensenii, Lactobacillus aci-
dophilus/gasserii, Lactobacillus crispatus, Lactobacillus rhamnosus, Lactobacillus casei/
paracasei, and Lactobacillus delbrueckii were very high, ranging from 192.86±26.73 mM
to 200 mM, when compared with the ones for pathogenic microbes. Fascinatingly, greater
minimum bactericidal concentration (MBCEP) values (>200 mM) of Lactobacillus spp. were
observed, signifying the harmlessness of EP for the beneficialmicrobiota of the host. Generally,
potentially pathogenic microbes were more susceptible to EP, whilst the beneficial isolates
resisted (p<0.0001) (Fig 2A and 2B).
Ethyl pyruvate inhibits the growth of a wide panel of fungal and bacterial
pathobionts
Fungal infection caused by moulds, dermatophytes and yeasts have been health problem of
both healthy and immunocompromised individuals [20]. Notably, Dermatophytes andMalas-
sezia spp., have been the leading etiologic agents for skin diseases, resulting in a significant
morbidity, discomfort, and disfigurement [21]. Furthermore,Aspergillus fumigatus, is the most
Table 1. Distribution of identified vaginal isolates and their MIC, MBC and MFC values.
Microorganisms Species Number of isolates (%) MIC (Mean±SD) MFC/MBC (Mean±SD)
Candida species Candida albicans 57 (38.8) 25±0 25±0
Candida glabrata 11 (7.5) 28.41±4.87 35.83±9.91
Candida tropicalis 10 (6.8) 25±0 25±0
Candida parapsilosis 15 (10.2) 25±0 25±0
Candida krusei 5 (3.4) 12.5±0 12.5±0
Others 10 (6.8) 18.75±6.59 25±14.43
Lactobacillus species Lactobacilus jensenii 14 (9.5) 192.86±26.73 >200
Lactobacillus acidophilus/gasserii 7 (4.76) 200±0 >200
Lactobacillus rhamnosus 2 (1.36) >200 >200
Lactobacillus casei/paracasei 2 (1.36) >200 >200
Lactobacillus crispatus 5 (3.4) 200±0 >200
Lactobacillus delbrueckii 1 (0.7) 200 200
Gram negative bacteria Escherichia coli 8 (5.44) 50±0 100±0
Total 147
Clinical isolates were cultured onto appropriate culture media and identified by Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF).
Minimum inhibitory and minimum bactericidal or fungicidal concentrations of ethyl pyruvate (EP) were determined by broth microdilution techniques. The
results are expressed in mean ± SD (n = 3).
doi:10.1371/journal.pone.0162919.t001
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frequent cause of invasive fungal infection primarily in the lung, causing a high mortality and
morbidity in immunocompromised individuals [22]. In this line, we have extended our survey
and analyzed the growth inhibitory potential of EP against a number of fungal pathobionts
including Dermatophytes and moulds. Most Dermatophytes could be growth-inhibited by
least 5mM EP with the exception ofMicrosporum gypseum, which was dumped at 10 mM EP
(Table 2). A representative example is shown for Trichophyton mentagrophytes, Trichophyton
tonsurans, Aspergillus fumigatus and Candida albicans (Fig 3A–3C). Surprisingly, the growth
of Aspergillus fumigatus was completely inhibited at 5mM EP (Fig 3B). We further evaluated
the growth inhibitory potential of EP against clinically relevant pathobionts such as non-spore
forming anaerobes, Gram negative oxidase positive bacteria,Clostridium spp.,Helicobacter
pylori, Gram positive cocci, and Salmonella spp. Accordingly, the minimum inhibitory concen-
tration of EP against these pathobionts was ranged from 10 to 40 mM (Fig 3D).
Ethyl pyruvate inhibits formation of Candida albicans biofilms and
promotes resolution of mature biofilms
Beside vaginal, oral candidiasis and additional superficial infections, systemic infection by Can-
dida spp. is linked with serious life-threatening conditions [23]. The crucial virulent factors of
Candida albicans is its ability to grow in a variety of morphological forms, ranging from unicellu-
lar budding yeast to filamentous form, that are able to invade tissues and overcome immune
response [24]. Moreover, particularlyCandida albicans are known to form biofilms on implants,
mucosal surfaces and vaginal epithelial cells [6]. The inhibitory activity of EP against Candida
albicans planktonic cells as shown in Fig 2B prompted us to study the effect of EP on Candida
albicans biofilm formation and resolution in vitro (Fig 4). EP inhibited formation of Candida
albicans biofilm in a dose-dependentmanner already at sub-inhibitory concentrations indicated
by lowMICEP values (P = 0.02 for 0.4 and 0.5xMICEP) (Fig 4A). At concentrations of 0.8xMICEP
biofilm formation was almost completely blocked (P<0.0001). In contrast to EP, EL had no
effect on Candida albicans biofilm formation indicating the requirement of certain structural ele-
ments in the molecule to be effective (Fig 4B). For comparison, biofilm formation could not be
inhibited by the standard antifungal drugAmphotericin B (AmpB) at least at concentrations
equivalent to 2xMICAmpB (P = 0.01) (MIC AmpB = 0.38 μg/mL) (Fig 4C). Fluorescence
Fig 2. Effect of ethyl pyruvate on growth of planktonic pathobionts. (a) Representative diagram of MIC
determination for E. coli, Lactobacillus spp. and Candida spp. in 96-well plate. The final EP concentration ranging
from 0.39 to 200 mM; growth control (GC), and sterility control (SC). White spots in the wells depict the growth of
tested isolates. (b) Selective anti-microbial activity of EP against pathobionts, e.g. Candida spp. (n = 108),
Escherichia coli (n = 8), and Lactobacillus spp. (n = 31) (***P< 0.0001).
doi:10.1371/journal.pone.0162919.g002
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microscope analysis revealed complex and dense yeast cells as well as hyphae encased in a matrix
in non-treated samples (Fig 4D). Clearly, EP-treated samples were unable to develop biofilms
(Fig 4E–4G) and yeast cells number vanished in a concentration dependentmanner.
EP exerted inhibitory activity also against pre-formedCandida albicans biofilm.After incuba-
tion of matured biofilms with EP for 24 h, a decideddestructionof pre-formed biofilms was
recorded. Interestingly, EP significantly decreasedmetabolic activity of pre-formed biofilms
already at 1xMICEP concentration (Fig 4H), which is not seenwith the conventional antifungal
drugAmpB (Fig 4J). This is furtherwitnessed by the finding that high concentrations of AmpB
(8x and 16xMICAmpB) had to be applied to obtain a significant reduction of pre-formed biofilms.
Table 2. Effect of ethyl pyruvate on dermatophytes.
Species Concentration (mM) Days
2 4 6 14 21
Trichophyton mentagrophytes Control 0 + + + + +
EP 1 - - - + +
5 - - - - -
10 - - - - -
Trichophyton interdigitale Control 0 + + + + +
EP 1 - - - (+) +
5 - - - - -
10 - - - - -
Microsporum gypseum Control 0 + + + + +
EP 1 + + + + +
5 - - - - +
10 - - - - -
Microsporum canis Control 0 + + + + +
EP 1 - - (+) + +
5 - - - - -
10 - - - - -
Trichophyton rubrum I Control 0 + + + + +
EP 1 - - - (+) +
5 - - - - -
10 - - - - -
Trichophyton rubrum II Control 0 + + + + +
EP 1 - - (+) + +
5 - - - - -
10 - - - - -
Trichophyton tonsurans I Control 0 - + + + +
EP 1 - - - (+) +
5 - - - - -
10 - - - - -
Trichophyton tonsurans II Control 0 - - - + +
EP 1 - - - - -
5 - - - - -
10 - - - - -
Culture media containing ethyl pyruvate (EP) at different concentrations and control media without EP were prepared. Standardized microbial suspension
was poured onto plates and incubated for certain time at appropriate temperature and followed by microbial growth investigation and recording. Accordingly,
+ = growth, (+) = growth doubtful,– = no growth.
doi:10.1371/journal.pone.0162919.t002
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Again, EL displayed no effect on matured Candida albicans biofilms (Fig 4I). These results were
confirmedby invertedmicroscopy analysis clearly showing a densemultilayered network of yeast
cells and hyphae in non-treatedmatured biofilms (Fig 4K). The complete destructionof pre-
formed biofilms including dissolution of the matrix upon EP treatment is presented in Fig 4L.
Ethyl pyruvate disperses the matrix of biofilms prepared in silicone tubes
under dynamic fluid condition
Bacterial pathobionts are capable of forming complex biofilms that potentially results in several
infections. Explicitly, cystic fibrosis, native valve endocarditis, otitis media, periodontitis
Fig 3. Inhibition by ethyl pyruvate of the growth of a wide panel of fungal and bacterial pathobionts. (a) Cultures of Trichophyton mentagrophytes
(left, white) and Trichophyton tonsurans I (right, yellow) were treated with different concentration of EP (0, 1 and 5 mM) for 24 hours. Cultures of
Aspergillus fumigatus (b) and Candida albicans (c) were treated by EP at 0, 1, 5, and 10 concentrations (mM). (d) Minimum (Min) and maximum (Max)
inhibitory concentration of EP for different bacteria, fungi and moulds (S1 Fig).
doi:10.1371/journal.pone.0162919.g003
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Fig 4. Ethyl pyruvate inhibits formation and dispersion of Candida albicans biofilms. Biofilms were grown in a 96-well tissue culture plates in the
presence of ethyl pyruvate (EP) (a), ethyl lactate (EL) (b) and Amphotericin B (AmpB) (c). The corresponding MIC-values were obtained from planktonic cell
studies. Fluorescence microscopic analysis revealed the effect of EP on Candida albicans biofilms formation (d-g). Non-treated biofilms showing dense
yeast cells (single arrow) and hyphae (triple arrow) and the extracellular matrix (double arrow) casing the yeast cells (d). Treatment of cells by 10, 25, and
50 mM EP is shown in e, f and g, respectively. Calcofluor staining was used to generate the images at x10 magnification using fluorescence microscopy.
Dispersion of matured Candida albicans biofilm by EP (h), EL (i) and AmpB (j). An inverted light microscopic analysis of non-treated pre-formed Candida
albicans biofilms shows filamentous biofilms containing both hyphae and yeast cells (k). Destructed biofilm by EP (4xMIC) displays no cells and hyphae (l).
Results are mean ± standard error of the mean of three independent experiments. *p<0.05; **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0162919.g004
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chronic prostatitis are appeared to be due to bacterial biofilms [5]. Remarkably, bacterial bio-
film infections are from both Gram-positive and Gram-negative bacteria that might be origi-
nated from the skin, from contact with other individuals or from tap water [25]. We have
developed bacterial biofilms under dynamic fluid condition using tap water as a source and
treated them with EP, EL, and Penicillin/Streptomycin (Pen/Strep). The experimental results
demonstrate a 3xlog10 reduction of the number of colony-forming units of the biofilms upon
exposure to 50 mM of EP (Fig 5A). In contrast, EL and Pen/Strep only marginally reduced the
colony-forming units from 4xlog10 to 3.3 and 3xlog10 CFU/mL, respectively (Fig 5B).
Fig 5. Destruction by ethyl pyruvate of biofilms prepared under dynamic fluid condition. (a) Colony forming units derivable from biofilms before and
after treatment with ethyl pyruvate (EP) in silicone tubes. (b) Treatment of matured biofilms in silicone tubes by 50 mM EP and 50 mM ethyl lactate (EL) as
well as Penicillin/Streptomycin (0.28/0.17 mM) as a control. Destruction of biofilm in the presence of antibacterial compounds was evaluated at different time
intervals. Scanning electron microscopy clearly shows well-structured matured biofilm, containing microorganisms encased in extracellular matrix (c, d). EP
treatment (50mM) displays few cells, cell debris and dissolution of extracellular matrix (e, f). Representative profile of MALDI-TOF mass spectrum of the
identified Sphingomonas paucimobilis from the silicone tube biofilm (g).
doi:10.1371/journal.pone.0162919.g005
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Moreover, biofilm destruction by EP became apparent already after 4 h of treatment. Inspec-
tion of biofilm by scanning electronmicroscopy revealed a very dense and complex structure
of matured biofilms showing poly-microbial communities encased within the matrix of extra-
cellular polymeric substances (Fig 5C and 5D). After treatment of the biofilmwith EP the num-
ber of encasedmicrobes tremendously decreased and only few vital cells were left surrounded
by cell debris. Surprisingly, EP distorted the biofilmmorphology not only by cell growth inhibi-
tion but also by dissolution of the biofilmmatrix (Fig 5E and 5F). Notably, no matrix destruc-
tion was observed in case of EL. This enables EP to become a potent agent to inhibit microbes’
adhesion, biofilm colonization, cell proliferation and to promote matrix destruction.
Ethyl pyruvate ignores resistance of microbes against a common drug
In invasive fungal infections,Candida spp., mould and Aspergillus spp. are absolutely the domi-
nating pathogens. The fluconazole-susceptible clinical isolate, Candida albicans (CA 8668),
showed a MIC of 16 μg/mL fluconazole and hence is a susceptible dose-dependent (SDD)
strain according to the CLSI guidelines [26]. The fluconazole-resistant strain, Candida albicans
(CA II64), displayed a MIC of 64 μg/mL. Both strains were tested for their capability to grow in
response to EP treatment (Fig 6A and 6B). In the presence of 2% glucose in the medium EP
effectively inhibited the growth of the fungi irrespective of their degree of sensitivity to flucona-
zole. Recovery tests that were performed by long-term incubation (two weeks) of the strain
treated before with 20 mM EP for two 24 hours showed no cell growth at all, indicating com-
plete cell killing.When yeast cells were grown in medium favouring gluconeogenesis (3%
Fig 6. Growth inhibition of fluconazole-resistant and susceptible Candida albicans by ethyl pyruvate. The
growth of both resistant and non-resistant Candida isolates in the presence of glucose was inhibited by EP (a, b),
whereas when gluconeogenesis was initiated with 3% glycerol/ethanol (GE) medium (c, d).
doi:10.1371/journal.pone.0162919.g006
Ethyl Pyruvate Combats Biofilms
PLOS ONE | DOI:10.1371/journal.pone.0162919 September 22, 2016 13 / 19
glycerol/ethanol (GE) medium) instead of glycolysis (2% glucosemedium) the efficacy of EP
was slashed (Fig 6C and 6D). This indicates that EP primarily inhibits growth of those cells
that exhibit a high glycolytic throughput. On the other hand, it offers the possibility to boost
the inhibitory action of EP by co-stimulation of the glycolysis.
Discussion
In humans bacteria, fungi, virus and archaea live together in communities (microbiota), and
colonize different parts of the body, such as the gut, oral cavity, skin, eyes and vagina [27].
Growing evidence supports the notion that alteration of the microbiota equilibriumhas a
strong influence on health and disease in humans [28]. Factors contributing to this alteration
are diet, genetics, environment, antibiotic intake and age [29]. This may consequently result in
conditions of dysbiosis that will end up in either a reduction in the number of symbionts, an
imbalance between the distinct symbionts and/or an increase in the number of pathobionts
[30]. That exigently calls for the development of pathobiont-targeted anti-microbial agents.
Moreover, many microbial pathogens are capable of forming biofilms resulting in persistent
infections that are difficult to treat and capable of evading the host immune system [25]. Bio-
films are formed when bacteria, fungi and/or algae adhere to biotic or abiotic surfaces encase
themselves in an extracellularmatrix and grow as sessile communities [5]. Biofilm develop-
mental stages comprise at least three major events: (i) initial attachment, (ii) biofilmmatura-
tion, and (iii) dispersal [31]. After surface attachment biofilmmaturate through cell division
and the production of the extracellular polymericmatrix. Biofilmmatrix varies between strains,
but in general can contain host factors, polysaccharide, proteins, and extracellular DNA.
Mostly, negatively charged polymeric sugars and DNA are bridged by Ca++ ions which stabilize
the matrix architecture. In order to coordinate the formation of biofilms, microorganisms use a
cell-to-cell communication system called quorum sensing (QS). It involves signal molecules
called auto-inducers that are released by the microbes themselves such as peptides (Gram-posi-
tive bacteria) or lipid-basedmolecules (Gram-negative bacteria) or farnesol (fungi) [32]. Once
the population reached a specific density or threshold, expression of certain genes such as viru-
lence factors and adhesion proteins can occur. Biofilm-related infectionsmay account for more
than 65% of all microbial infections in the human body [33].
Methods employed for preventing and eliminating biofilms are limited in their efficacy on
mature biofilms. Despite this a number of anti-biofilm formulations and technologies that
include ethylenediaminetetraacetic acid (EDTA) [34], surface-coated nanoparticles [35], small
molecular organic compounds [36], weak acids [37], silver [38] and monoclonal antibodies
[39] have demonstrated efficacy on in vitro biofilms. Still, there is a need for agents that act
against both planktonic cells and biofilm and exert minimal tissue-irritating effects.
As learned from cancer research, EP, when used in comparable concentrations inhibited
tumor cells growth effectively, most probably by targeting enzymes of the glycolytic pathway
[11, 13, 14]. Contact with EP induced necroptosis of cancer cells primarily by induced deple-
tion of ATP and the formation of the toxic methylglyoxal. Since the glycolytic chain is highly
conserved in almost all microbes investigated it is likely to assume similar mechanism of action
of EP as in mammalian cells. This is corroborated by the findings that EP is less toxic to cells
when they gain their energy from gluconeogenesis instead of glycolysis (Fig 6). This, on the
other hand, means that the toxicity of EP can be enhanced by metabolic activation of microbes
or whenmicrobes growth under nutrient-enriched condition. From the current point of
knowledge, EP has the edge over other anti-biofilm agents for several reasons: (i) no side effects
could be seen in clinical studies so far [40], (ii) it is tissue protective [10], (iii) it is inhibitory to
a broad spectrumof pathobionts (bacteria, fungi, moulds, parasites) and (iv) harmless to
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symbionts (Lactobacillus spp.), (v) there is a low chance of resistance development as EP is
aimed at multiple targets (vi) it inhibits biofilm adhesion and maturation, (vii) it dissolutes the
biofilmmatrix, (viii) it is environmentally safe [41].
The surprising different anti-microbial activity of EP and EL awaits explanation. Chemi-
cally, they differ only from two protons, which consequently allow EP to configure a dicarbonyl
structure [10]. This structural element is a prerequisite for inhibiting the enzymes GLO1 and
PK as EL revealed no effect at all. It may also disclose why many polyphenols such as curcumin
and resveratrol were reported to have anti-microbial activities [42, 43].
The potency of EP to dissolute pre-formed biofilm has to be emphasized. It most probably
relates to its property to chelate divalent ions such as Ca++ ions due to its dicarbonyl structure.
Targeting Ca++ ions in biofilms by EDTA has been proposed as treatment of infected wounds
[34].
Still a matter of discussion that remains is the millimolar concentration of EP needed to
assure inhibitory effects. Therefore, it is currently questionable for using it as a systemic drug
medication. However, an improvement of its activity could be anticipated by chemically
manipulating the core structure. Nevertheless, infusion of EP has already been applied in clini-
cal studies and no side effects of EP in humans were reported [40]. In fact most microbial infec-
tions are located on the skin and mucosa such as in the vagina and gut. In this line, EP-grafted
dressings or polymers with a sustained release of EP into the wound bed or inflamed gut could
be a new option for wound care especially in surgery, diabetes and bowel diseases [44, 45].
It is suggested that chronic inflammation as typically observed in intestinal bowel disease
involves a combination ofmicrobial inflammation as well as sterile inflammation, the latter
induced by components of fragmented cells such as DNA or nuclear proteins like HMGB1.
Notably, EP is capable to act against both causes [46].
As far as bacterial vaginosis biofilms are concerned vaginal tampons containing EP could be
used to reconstitute the vaginal microbiota. This is all the important as preservation of Lacto-
bacillus spp. in the mucosal fluids is a central issue in case of treatment with antibiotics.
The devastating effects of antibiotic resistance may look us into a disquieting prospect,
which threatens our dwindling antibiotic arsenal. Antibiotic resistance is a global problem lead-
ing to an increased economic and human cost in lives [47]. Notably, these changes in resistance
rates include increasing detection of extended spectrumbeta-lactamase (ESBL)-production in
Enterobacteriaceae, increasingmultidrug-resistance in P. aeruginosa and Acinetobacter spp.,
Methillicin-resistant Staphylococcus aureus (MRSA), as well as in Candida species. In addition,
Enterohemorrhagic Escherichia coli (EHEC), a food born human pathogen, has been account-
ing for outbreaks of bloody diarrhea and haemolytic uraemic syndrome especially in young
children and elderly worldwide [48]. In the present study we have shown for the first time that
EP inhibited microbes known to be resistant to most available drugs in the clinics.
Apart from clinical aspect, the applicability of EP could be extended to industrial level. As
biofilm forming microorganisms are highly prevalent in dead ends, corners, cracks, crevices,
gaskets, valves, medical devices and the joints of stainless steel equipment used in the dairy
manufacturing plants [49]. The removal of biofilms and planktonic cells within production
machinery in the paper, safety and hygienic food packaging industry [50], cooling water cir-
cuits e.g. in nuclear power stations, and drinkingwater manufacturing systems can be critical
for the safety and efficacyof those processes [51].
In summary, EP revealed a selective anti-microbial action against both potentially patho-
genic fungal and bacterial planktonic cells and complex biofilms. This intensifies the potential
of the compound specifically to be used as an anti-microbial agent against disease causing path-
ogens without affecting beneficial bacteria.
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Supporting Information
S1 Fig. Description of microbes tested in the gowth inhibitory assay. 1: Enterobacteriaceae:
Salmonella agona, Salmonella B(O:4), Salmonella derby, Salmonella brandenburg, Salmonella
corvallis, Salmonella london, Salmonella ohio, Salmonella goldcoast, E. coli Nissle, Enterohae-
morrhagic E. coli (EHEC); 2: Gram positive (GP) cocci: Staphylococcus aureus, Streprococcus
dysgalactiae ssp. dysgalactiae, Methicillin-resistant Staphylococcus aureus (MRSA); 3:Mycobac-
terium (M) phlei. 4:Helicobacter (H) pylori 5: Lactobacillus: Lactobacillus paracasei ssp. paraca-
sei, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus harbinensis, Lactobacillus
plantarum; 6: Clostridia: Clostridium cutyricum,Clostridium. baratii, Clostridium difficile, Clos-
tridium chauvoei, Clostridium sordellii, Clostridium septicum, Clostridium bifermentans, Clos-
tridium sporogenes, Clostridium botulinum type A-E, Clostridium novyi,Clostridium
perfringens type B-D, Clotridium tetanomorphum, Clostridium tetani; 7: Non-spore forming
(NSF) anaerobes: Porphyromonas gingivalis, Prevotella intermedia; 8: Gram- negative oxidative
positive (GNOP) isolates: Pseudomonas aeruginosa; Campylobacter jejuni, Campylobacter coli.
9: Yeast: Candida albicans, Candida parapsilosis, Candida kruzei, Candida tropicalis, Candida
valida, Candida lusitaniae, Candida pulcherrima, Candida glabrata, Candida zeylanoides, Can-
dida boidinii, Candida kefyr,Candida allociferii, Candida cacaoi/Pichia farinosa, Candida afri-
cana, Candida pararugosa, Candida colliculosa, Candida guilliermondii, Candida lipolytica,
Candida haemulonii, Candida dubliniensis, Candida norvegensis, Candida thermophilia, Can-
dida slooffiae, Sporomolomyces salmonicolor, Magnusiomyces capitatus, Rhodotorula glutinis,
Rhodotorula mucilaginosa, Trichosporon ovoides,Metschnikowia reukaufii, Malassezia pachy-
dermatis, Cryptococcus laurentii; Trichosporon debeurmanniam, 10: Dermatophytes: Tricho-
phyton mentagrophytes, Microsporum gypseum,Trichophyton rubrum,Microsporum canis,
Trichophyton interdigitale, Trichophyton tonsurans, Trichophyton mentagrophtes, Microsporom
audouinii; 11: Molds: Aspergillus fumigatus, Aspergillus flavus,Mucor spp., pseudallescheria,
Trichoderma spp., Aspergillus niger, Altenaria spp.; Min. IC =Minimum Inhibitory Concentra-
tion for the group; Max. IC =Maximum Inhibitory Concentration for the group.
(PDF)
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